

Supplementary Online Content

Williams SB, Shan Y, Jazzar U, et al. Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer. *JAMA Surg*. Published online June 27, 2018. doi:10.1001/jamasurg.2018.1680

eTable 1. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Clinical Stage

eTable 2. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Use of Chemotherapy Type in Trimodal Therapy

eTable 3. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Fractions Delivered (<18 v >18) in Trimodal Therapy Cohort

eTable 4. Proportional Hazards Regression Model of Predictors for Time-to-Death on Use of Neoadjuvant Chemotherapy Among Radical Cystectomy Cohort

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Clinical Stage

Stage 2				
Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	1.62	1.38	1.89	<0.001
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	1.76	1.42	2.18	<0.001
Stage 3				
Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	1.74	1.26	2.40	<0.001
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	1.40	0.90	2.19	0.138
Stage 4				
Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	0.94	0.72	1.23	0.663
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy	1.16	0.84	1.58	0.367

CI: Confidence interval; HR: Hazard ratio

eTable 2. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Use of Chemotherapy Type in Trimodal Therapy

Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy + Cisplatin or 5-FU and MMC	1.27	1.10	1.47	0.001
Trimodal Therapy + Other Chemotherapy	1.69	1.46	1.96	<0.001
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy + Cisplatin or 5-FU and MMC	1.50	1.23	1.83	<0.001
Trimodal Therapy + Other Chemotherapy	1.97	1.62	2.39	<0.001

5-FU: 5- fluorouracil; CI: Confidence interval; HR: Hazard ratio; MMC: mitomycin C

eTable 3. Proportional Hazards Regression Model of Predictors for Time-to-Death According to Fractions Delivered (<18 v >18) in Trimodal Therapy Cohort

Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy <18 fractions	1.39	1.16	1.68	<0.001
Trimodal Therapy >18 fractions	1.23	1.02	1.48	0.029
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Radical Cystectomy	ref	-	-	-
Trimodal Therapy <18 fractions	1.48	1.14	1.93	0.003
Trimodal Therapy >18 fractions	1.37	1.05	1.78	0.019

CI: Confidence interval; HR: Hazard ratio

* N=326, Median: 18 fractions. We counted number of fractions within 90 days after the first radiation treatment and defined number of fractions based on the number of radiation treatments delivered as billed in Medicare claims as part of the initial outpatient course of radiotherapy¹⁶.

eTable 4. Proportional Hazards Regression Model of Predictors for Time-to-Death on Use of Neoadjuvant Chemotherapy Among Radical Cystectomy Cohort

Covariate	Cox Regression			
	Overall Survival			
	HR	95% CI		p Value
Treatment				
Trimodal Therapy	ref	-	-	-
Radical Cystectomy + Neoadjuvant Chemotherapy	0.62	0.48	0.79	<0.001
Radical Cystectomy Alone	0.70	0.61	0.79	<0.001
Covariate	Competing Risk Regression			
	Cancer-Specific Survival			
	HR	95% CI		p Value
Treatment				
Trimodal Therapy	ref	-	-	-
Radical Cystectomy + Neoadjuvant Chemotherapy	0.53	0.37	0.76	<0.001
Radical Cystectomy Alone	0.59	0.49	0.71	<0.001

CI: Confidence interval; HR: Hazard ratio